Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Immunol ; 202(2): 441-450, 2019 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-30552163

RESUMEN

Zinc deficiency causes immune dysfunction. In T lymphocytes, hypozincemia promotes thymus atrophy, polarization imbalance, and altered cytokine production. Zinc supplementation is commonly used to boost immune function to prevent infectious diseases in at-risk populations. However, the molecular players involved in zinc homeostasis in lymphocytes are poorly understood. In this paper, we wanted to determine the identity of the transporter responsible for zinc entry into lymphocytes. First, in human Jurkat cells, we characterized the effect of zinc on proliferation and activation and found that zinc supplementation enhances activation when T lymphocytes are stimulated using anti-CD3/anti-CD28 Abs. We show that zinc entry depends on specific pathways to correctly tune the NFAT, NF-κB, and AP-1 activation cascades. Second, we used various human and murine models to characterize the zinc transporter family, Zip, during T cell activation and found that Zip6 was strongly upregulated early during activation. Therefore, we generated a Jurkat Zip6 knockout (KO) line to study how the absence of this transporter affects lymphocyte physiology. We found that although Zip6KO cells showed no altered zinc transport or proliferation under basal conditions, under activation, these KO cells showed deficient zinc transport and a drastically impaired activation program. Our work shows that zinc entry into activated lymphocytes depends on Zip6 and that this transporter is essential for the correct function of the cellular activation machinery.


Asunto(s)
Proteínas de Transporte de Catión/metabolismo , Síndromes de Inmunodeficiencia/metabolismo , Proteínas de Neoplasias/metabolismo , Linfocitos T/inmunología , Timo/patología , Zinc/metabolismo , Animales , Atrofia , Transporte Biológico , Proteínas de Transporte de Catión/genética , Proteínas de Transporte de Catión/inmunología , Proliferación Celular , Citocinas/metabolismo , Técnicas de Silenciamiento del Gen , Humanos , Células Jurkat , Activación de Linfocitos , Ratones , Ratones Endogámicos C57BL , Modelos Animales , FN-kappa B/metabolismo , Factores de Transcripción NFATC/metabolismo , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/inmunología , Transducción de Señal , Factor de Transcripción AP-1/metabolismo , Regulación hacia Arriba
2.
Immunol Invest ; 45(2): 148-60, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26854821

RESUMEN

Folk medicine has long employed leaves from Eriobotrya japonica Lindl. (Rosaceae) (LEJ) as relieving many diseases including chronic bronchitis and high fever. In this study, we investigated the immunomodulatory effects of leaves from LEJ water extracts (LEJE) in LP-BM5 murine leukemia viruses (MuLV)-induced immune-deficient animal model. Dietary supplementation of LEJE (100, 300, 500 mg/kg) began on the day of LP-BM5 MuLV infection and continued for 12 weeks. Dietary supplementation of LEJE inhibited LP-BM5 MuLV-induced splenomegaly and lymphadenopathy. Moreover, LEJE attenuated reductions of T- and B-cell proliferation and Th1/Th2 cytokine imbalance in LP-BM5. We found that dietary supplements of LEJE suppressed the hypergammaglobulinemia by ameliorating LP-BM5 MuLV infection-induced B-cell dysfunction and production of pro-inflammatory cytokines. We suggest that Eriobotrya japonica may have beneficial immunomodulatory effects, improving the balance of Th1/Th2 cytokines and anti-inflammatory effects.


Asunto(s)
Antivirales/farmacología , Eriobotrya/química , Síndromes de Inmunodeficiencia/inmunología , Síndromes de Inmunodeficiencia/virología , Virus de la Leucemia Murina , Extractos Vegetales/farmacología , Animales , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Antivirales/administración & dosificación , Antivirales/química , Ácido Clorogénico/química , Citocinas/metabolismo , Modelos Animales de Enfermedad , Femenino , Síndromes de Inmunodeficiencia/tratamiento farmacológico , Síndromes de Inmunodeficiencia/metabolismo , Mediadores de Inflamación/metabolismo , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , Linfocitos/efectos de los fármacos , Linfocitos/inmunología , Linfocitos/metabolismo , Ratones , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Bazo/citología , Bazo/inmunología , Bazo/metabolismo , Subgrupos de Linfocitos T/efectos de los fármacos , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/metabolismo
3.
Magnes Res ; 28(2): 46-55, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26422833

RESUMEN

Disturbances in magnesium homeostasis, often linked to altered expression and/or function of magnesium channels, have been implicated in a plethora of diseases. This review focuses on magnesium transporter 1 (MAGT1), as recently described changes in this gene have further extended our understanding of the role of magnesium in human health and disease. The identification of genetic changes and their functional consequences in patients with immunodeficiency revealed that magnesium and MAGT1 are key molecular players for T cell-mediated immune responses. This led to the description of XMEN (X-linked immunodeficiency with magnesium defect, Epstein Barr Virus infection, and neoplasia) syndrome, for which Mg2+ supplementation has been shown to be beneficial. Similarly, the identification of a copy-number variation (CNV) leading to dysfunctional MAGT1 in a family with atypical ATRX syndrome and skin abnormalities, suggested that the MAGT1 defect could be responsible for the cutaneous problems. On the other hand, recent genetic investigations question the previously proposed role for MAGT1 in intellectual disability. Understanding the molecular basis of the involvement of magnesium and its channels in human pathogenesis will improve opportunities for Mg2+ therapies in the clinic.


Asunto(s)
Proteínas de Transporte de Catión/fisiología , Síndromes de Inmunodeficiencia/genética , Discapacidad Intelectual/genética , Animales , Humanos , Síndromes de Inmunodeficiencia/diagnóstico , Síndromes de Inmunodeficiencia/metabolismo , Discapacidad Intelectual/diagnóstico , Discapacidad Intelectual/metabolismo , Magnesio/metabolismo , Enfermedades por Inmunodeficiencia Combinada Ligada al Cromosoma X/diagnóstico , Enfermedades por Inmunodeficiencia Combinada Ligada al Cromosoma X/genética , Enfermedades por Inmunodeficiencia Combinada Ligada al Cromosoma X/metabolismo
4.
Langenbecks Arch Surg ; 386(5): 369-76, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11685569

RESUMEN

BACKGROUND: Immunonutrition with omega-3 fatty acids and the "conditionally essential" amino acids arginine, glutamine, cysteine, and taurine can enhance the immune response in critically ill patients. This is due to the immunomodulating properties of these nutrients. Immunonutrition is especially important when a patient's immune response is compromised, as is the case post-operatively or after trauma. Immune deficiency is severely aggravated in sepsis and the systemic inflammatory response syndrome (SIRS). The resulting metabolic stress is characterized by glycolysis, lipolysis, and proteolysis, which may escalate to an hypercatabolic response or "autocannabilism." Catabolic metabolism results in insufficiency of both specific and unspecific immunocompetent cells. CONCLUSIONS: Immunonutrition should be started early in such patients for an optimal beneficial effect, preferably via the enteral route. It should include medium chain and long chain triglycerides, polyunsaturated omega-3 and omega-6 fatty acids (in the ratio 1:2), olive oil, and conventional amino acid preparations supplemented with the conditionally essential amino acids arginine, glutamine, cysteine, and taurine.


Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Aminoácidos Esenciales/uso terapéutico , Enfermedad Crítica , Suplementos Dietéticos , Ácidos Grasos Omega-3/uso terapéutico , Huésped Inmunocomprometido/fisiología , Síndromes de Inmunodeficiencia/dietoterapia , Endotoxinas/sangre , Nutrición Enteral/métodos , Humanos , Síndromes de Inmunodeficiencia/etiología , Síndromes de Inmunodeficiencia/metabolismo , Metabolismo de los Lípidos , Proteínas/efectos de los fármacos , Proteínas/metabolismo , Transducción de Señal/efectos de los fármacos
5.
J Immunol ; 162(8): 4998-5002, 1999 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-10202048

RESUMEN

The mechanisms for activating the hypothalamic-pituitary-adrenal (HPA) axis and the roles glucocorticoids play in the pathogenesis of chronic infectious disease are largely undefined. Using the LP-BM5 model of retrovirus-induced immunodeficiency, we found alterations in HPA axis function, manifested as an increase in circulating levels of adrenocorticotropic hormone and corticosterone, beginning after only 3 mo of infection. These changes occurred contemporaneously with a shift in the profile of circulating cytokines from a Th1-dominant (IFN-gamma) to Th2-dominant (IL-4, IL-10) phenotype. No significant changes in either circulating IL-1beta, IL-6, or TNF-alpha levels were observed in infected mice. Administering the N-methyl-D-aspartate receptor antagonist MK-801 to infected mice normalized plasma adrenocorticotropic hormone and corticosterone levels, indicating that glutamate was a major activator of the HPA axis. Moreover, MK-801 treatment of late-stage mice also reversed the type 1 to type 2 cytokine shift to a degree comparable or superior to treatment with the glucocorticoid receptor antagonist RU-486. These findings indicate that HPA axis activation during LP-BM5 retrovirus infection is mediated by the chronic hyperactivation of glutamatergic pathways in the hypothalamus. Through this mechanism, the degree of peripheral immunodeficiency observed in the late-stage disease is profoundly augmented.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Ácido Glutámico/fisiología , Sistema Hipotálamo-Hipofisario/inmunología , Síndromes de Inmunodeficiencia/inmunología , Virus de la Leucemia Murina/inmunología , Sistema Hipófiso-Suprarrenal/inmunología , Animales , Citocinas/sangre , Citocinas/fisiología , Maleato de Dizocilpina/administración & dosificación , Ácido Glutámico/inmunología , Sistema Hipotálamo-Hipofisario/metabolismo , Sistema Hipotálamo-Hipofisario/virología , Síndromes de Inmunodeficiencia/metabolismo , Síndromes de Inmunodeficiencia/fisiopatología , Bombas de Infusión , Masculino , Ratones , Ratones Endogámicos C57BL , Sistema Hipófiso-Suprarrenal/metabolismo , Sistema Hipófiso-Suprarrenal/virología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores
6.
Am J Med ; 86(6 Pt 2): 791-800, 1989 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2543220

RESUMEN

PURPOSE: Invasive aspergillosis in the immunocompromised host is one of the most difficult therapeutic problems. Itraconazole, a new oral triazole, is inhibitory as well as fungicidal against Aspergillus species in vitro. It is active against Aspergillus infections in animal models. We present our experience with itraconazole therapy of 21 patients with aspergillosis. PATIENTS AND METHODS: Eighteen of the 21 patients received 400 mg of itraconazole orally per day; the other three received 100 to 200 mg daily. Serum concentrations of itraconazole were measured and susceptibility testing was performed according to previously described methods. RESULTS: Of 15 evaluable patients, responses were produced in 12. Four of five with invasive pulmonary disease, two of two with skeletal disease, one of two with pleural disease, one of one with pericardial, sinus, mastoid, or hepatosplenic aspergillosis, and one of one with onychomycosis responded. One patient with carotid artery disease did not show a response, although results of cultures were negative at autopsy. One responder with joint disease had a possible relapse three months after completing 12 months of therapy. Ten of these patients were immunocompromised (including four with neutropenia and two renal transplant recipients) and eight of these responded. Side effects with itraconazole, in contrast to previously available therapy, were rare. CONCLUSION: This experience suggests itraconazole may be an important advance in the therapy of aspergillosis.


Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Cetoconazol/análogos & derivados , Adulto , Anciano , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Aspergilosis/diagnóstico , Aspergilosis/metabolismo , Aspergilosis/microbiología , Aspergillus flavus/efectos de los fármacos , Aspergillus flavus/aislamiento & purificación , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/aislamiento & purificación , Evaluación de Medicamentos , Femenino , Humanos , Síndromes de Inmunodeficiencia/tratamiento farmacológico , Síndromes de Inmunodeficiencia/metabolismo , Síndromes de Inmunodeficiencia/microbiología , Itraconazol , Cetoconazol/farmacocinética , Cetoconazol/farmacología , Cetoconazol/uso terapéutico , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad
7.
J Immunol ; 142(2): 388-93, 1989 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-2463304

RESUMEN

Vitamin A-deficient mice exhibited sharply decreased IgG1 responses to protein Ag in vivo and in vitro. We traced the cellular basis for these impaired responses to a functional defect in A-deficient Th. Ag-presenting cells and B cells from A-deficient mice showed no functional defects. The A-deficient T cells proliferated normally in response to Ag but failed to provide the B cell stimulus for Ag-specific IgG1 responses. The A-deficient mice had fewer Th by limiting dilution analysis, and retinyl acetate supplementation in vitro restored Th frequency to control levels. Because added retinyl acetate reversed the Th functional block, these vitamin A-deficient T cells must be primarily defective in activation, not in establishment of immunologic memory.


Asunto(s)
Síndromes de Inmunodeficiencia/etiología , Linfocitos T Colaboradores-Inductores/inmunología , Deficiencia de Vitamina A/inmunología , Animales , Linfocitos B/inmunología , Epítopos , Inmunoglobulina M/biosíntesis , Síndromes de Inmunodeficiencia/metabolismo , Memoria Inmunológica , Recuento de Leucocitos , Activación de Linfocitos , Macrófagos/inmunología , Ratones , Ratones Endogámicos , Linfocitos T Colaboradores-Inductores/metabolismo , Deficiencia de Vitamina A/complicaciones , Deficiencia de Vitamina A/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA